ADCC News and Research

RSS

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Researchers evaluated the neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 sub-variants by therapeutic monoclonal antibodies.

16 Aug 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

High-level resistance of SARS-CoV-2 BA.4 against neutralizing antibodies

Researchers evaluates the sensitivity of BA.4 in both vaccinated and unvaccinated individuals infected with the SARS-CoV-2 variants.

20 Jul 2022

Immunoglobulin G isotypes switch class following repeated SARS-CoV-2 mRNA vaccination

Researchers reported a class switch in SARS-CoV-2-specific antibodies due to repeated mRNA vaccinations.

13 Jul 2022

Scientists investigate impact of SARS-CoV-2 RBD mutations across variants

In a recent study posted to the medRxiv* pre-print server, Australian researchers comprehensively investigated the impact of 39 receptor-binding-domain (RBD) mutations in six severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs).

12 Jul 2022

Patient-derived antibody cocktail active across SARS-CoV-2 variants of concern

In a recent study published in the journal Science Immunology, researchers in the United States described a rare anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) three antibody cocktail IMM-BCP-01.

4 Jul 2022

Fc-effector functions for selecting COVID-19 convalescent plasma

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that coronavirus disease 2019 (COVID-19) convalescent plasmas (CCPs) with low neutralizing and high fragment crystallizable (Fc)-effector activity result in effective prophylaxis.

15 Jun 2022

Immunity conferred by COVID-19 vaccines in solid organ transplant recipients

In a recent study posted to the medRxiv* preprint server, researchers estimated the humoral immunity imparted by the two/three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in solid organ transplant recipients (SOTRs).

18 May 2022

Review aims to deepen the understanding of the role of natural killer cells in COVID-19

In a recent study published in Biomedicines, researchers explored the utility of natural killer (NK) cells in coronavirus disease 2019 (COVID-19).

28 Apr 2022

Antibody dependent cellular cytotoxicity may influence HIV transmission from mother to child during breastfeeding

According to new research from Boston Medical Center, the antibody function known as antibody dependent cellular cytotoxicity (ADCC) and the ADCC sensitivity of HIV strains may influence the transmission of HIV from mother to child during breastfeeding.

21 Apr 2022

SARS-CoV-2 ORF8 interferes with antibody-dependent cellular cytotoxicity

Researchers describe the effect of ORF8 and the immune-evasion activity used by SARS-CoV-2 to escape humoral responses.

5 Apr 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Researchers conducted a comprehensive and systematic analysis of functional SARS-CoV-2 antibody profiles in a controlled randomized trial of severe COVID-19 hospitalized individuals treated with COVID-19 CCP.

25 Feb 2022

Superior immune response in vaccinated after infection with Omicron compared to unvaccinated

In a recent study posted to the medRxiv* preprint server, researchers evaluated the cross-reactivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-triggered neutralization and fragment crystallizable (Fc) effector functions between coronavirus disease 2019 (COVID-19)-vaccinated and unvaccinated individuals in South Africa.

16 Feb 2022

Researchers develop a universal SARS-CoV-2 neutralizing antibody

A new study has been published in Frontiers in Immunology, where scientists developed a universal SARS-CoV-2 neutralizing antibody, MG1141A.

13 Dec 2021

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.

1 Dec 2021

The SARS-CoV-2 Beta variant evades Fc effector function by ancestral strain, study says

A new study finds improved Fc cross-reactivity against certain SARS-CoV-2 variant of concern.

10 Nov 2021

The role of T follicular helper cells in the humoral immune response to SARS-CoV-2

The current analysis indicates that cTfh cells react to the spike antigen following vaccination are associated with anti-S protein neutralizing antibodies.

9 Nov 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021